Los Angeles, California 90027

  • Pancreatic Cysts

Purpose:

Our hypothesis is that a single dose of antibiotics at time of EUS-guided pancreatic cyst aspiration is equally effective to the usual regimen of 3 days of post-procedural antibiotics.


Study summary:

With the increased use of cross sectional imaging, there appears to be an increasing prevalence of pancreatic cysts being incidentally discovered. A critical step in the workup of pancreas cysts is to determine whether the cyst is mucinous or non-mucinous, through a procedure called endoscopic ultrasound - fine needle aspiration (EUS-FNA). Current guidelines suggest the use of antibiotics in cyst aspiration, usually 3 days after the procedure. However, these recommendations are based on limited data from over 15 years ago. More recent retrospective observations suggest equivalent safety when little, or even no antibiotics are given.


Criteria:

Inclusion Criteria: - Patients between the age of 18-90 who present for an EUS / pancreas cyst evaluation Exclusion Criteria: - Patients outside the age range - Patient-related factors (unable to provide consent, unable to understand English, allergic to cipro) - High-risk patients for infective endocarditis - Bacterial infection or use of antibiotics within 6 weeks of EUS - Pancreatitis within the past 6 months - Underlying immunosuppression (for example, uncontrolled diabetes - such as hemoglobin A1c above 7 or glucose > 180; renal failure; cirrhosis; pre-existing malignancy especially hematologic malignancy such as leukemia / lymphoma / multiple myeloma; HIV/AIDS) - Currently taking immunosuppressive medications (for conditions such as rheumatoid arthritis, inflammatory bowel disease, organ transplant) - Radiographic or endosonographic evidence of cyst cavity debris / necrotic debris - Severe systemic disease (for example, NYHA class III or IV heart failure, oxygen-dependent COPD)


NCT ID:

NCT01929460


Primary Contact:

Karl Kwok, MD
Phone: 323-783-6830
Email: Regional-Research-Committee@kp.org


Backup Contact:

N/A


Location Contact:

Los Angeles, California 90027
United States

Karl Kwok, MD
Phone: 323-783-6830
Email: Regional-Research-Committee@kp.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.